MOTACABTAGENE LUREVGEDLEUCEL
UNII 7CH7MR6SN5

Substance Identification & Data

This profile provides standardized clinical and technical data for Motacabtagene Lurevgedleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 7CH7MR6SN5.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
7CH7MR6SN5
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
MOTACABTAGENE LUREVGEDLEUCEL
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C172741
National Cancer Institute reference terminology for clinical and research data.
INN ID
11721
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Motacabtagene Lurevgedleucel
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
ITIS TSN
180092
Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.
NCBI Taxonomy
9606
Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Motacabtagene Lurevgedleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Motacabtagene Lurevgedleucel

Common Names & Synonyms

ALLOGENEIC T CELLS OBTAINED FROM PERIPHERAL BLOOD BY LEUKAPHERESIS, GENETICALLY MODIFIED BY CRISPR/CAS9 (CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS/CRISPR-ASSOCIATED PROTEIN 9) MEDIATED GENE EDITING CONSISTING OF TWO GUIDE RNAS (GRNAS) INTRODUCED TRANSIENTLY AS CAS9-GRNA RIBONUCLEOPROTEIN (RNP) COMPLEX FOR THE TARGETED DISRUPTION OF THE T CELL RECEPTOR ALPHA CHAIN CONSTANT (TRAC) AND .BETA.2 MICROGLOBULIN (B2M) LOCI AND THE INSERTION OF AN ANTI-B CELL MATURATION ANTIGEN (BCMA) CAR TRANSGENE INTO THE TRAC LOCUS VIA AN ADENO-ASSOCIATED VIRUS SEROTYPE 6 (AAV6) VECTOR. THE CAR IS COMPOSED OF A HUMANIZED SINGLE-CHAIN VARIABLE FRAGMENT (SCFV) TARGETING BCMA, FOLLOWED BY A CD8 HINGE AND TRANSMEMBRANE REGION, A 4-1BB (CD137) COSTIMULATORY DOMAIN AND A CD3.ZETA. SIGNALLING DOMAIN. EXPRESSION OF THE CAR IS DRIVEN BY THE ELONGATION FACTOR, EF-1.ALPHA., PROMOTER AND IS TERMINATED BY A SYNTHETIC POLY A SEQUENCE. THE BCMA EXPRESSION CASSETTE IS FLANKED BY TWO TRAC HOMOLOGY ARMS GUIDING THE EXPRESSION CASSETTE TO THE TRAC LOCUS. THE T CELLS ARE CULTURED IN THE PRESENCE OF GROWTH MEDIUM CONTAINING INTERLEUKIN 2 (IL-2) AND 7 (IL-7) AND ARE 30% CAR+ T CELLS, 0.4% TCR+ AND 30% B2M+
motacabtagene lurevgedleucel [INN]

External Clinical & Regulatory Resources

NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus